Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,381 Shares

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,381 shares of Natera stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $24.10, for a total transaction of $33,282.10. Following the completion of the sale, the chief financial officer now owns 21,179 shares of the company’s stock, valued at approximately $510,413.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

  • On Tuesday, March 10th, Michael Burkes Brophy sold 787 shares of Natera stock. The stock was sold at an average price of $33.36, for a total transaction of $26,254.32.
  • On Thursday, February 27th, Michael Burkes Brophy sold 200 shares of Natera stock. The stock was sold at an average price of $40.00, for a total transaction of $8,000.00.
  • On Monday, February 3rd, Michael Burkes Brophy sold 2,251 shares of Natera stock. The stock was sold at an average price of $35.22, for a total transaction of $79,280.22.
  • On Thursday, January 2nd, Michael Burkes Brophy sold 625 shares of Natera stock. The stock was sold at an average price of $33.86, for a total transaction of $21,162.50.

NTRA stock opened at $25.90 on Friday. The company has a market capitalization of $2.04 billion, a P/E ratio of -14.31 and a beta of 1.13. The company has a 50-day simple moving average of $33.35 and a 200 day simple moving average of $35.26. Natera Inc has a fifty-two week low of $16.87 and a fifty-two week high of $41.80. The company has a quick ratio of 2.84, a current ratio of 2.91 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.16. The business had revenue of $83.20 million during the quarter, compared to the consensus estimate of $77.84 million. Natera had a negative net margin of 41.30% and a negative return on equity of 120.68%. Equities analysts anticipate that Natera Inc will post -2.36 EPS for the current year.

A number of analysts recently issued reports on the stock. ValuEngine upgraded shares of Natera from a “hold” rating to a “buy” rating in a research note on Wednesday, March 18th. Canaccord Genuity reiterated a “buy” rating and set a $46.00 target price on shares of Natera in a research note on Thursday, March 19th. Piper Sandler boosted their target price on shares of Natera from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Craig Hallum reiterated a “buy” rating and set a $49.00 target price on shares of Natera in a research note on Thursday, December 19th. Finally, Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Natera currently has an average rating of “Buy” and a consensus target price of $43.00.

A number of hedge funds have recently bought and sold shares of the stock. Nuveen Asset Management LLC lifted its holdings in Natera by 4.7% in the fourth quarter. Nuveen Asset Management LLC now owns 1,061,355 shares of the medical research company’s stock worth $35,757,000 after purchasing an additional 47,836 shares during the period. Norges Bank acquired a new stake in Natera in the fourth quarter worth about $20,893,000. Geode Capital Management LLC lifted its holdings in Natera by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 916,590 shares of the medical research company’s stock worth $30,879,000 after purchasing an additional 89,493 shares during the period. Alliancebernstein L.P. lifted its holdings in Natera by 0.7% in the fourth quarter. Alliancebernstein L.P. now owns 76,000 shares of the medical research company’s stock worth $2,560,000 after purchasing an additional 500 shares during the period. Finally, Man Group plc lifted its holdings in Natera by 114.4% in the fourth quarter. Man Group plc now owns 182,457 shares of the medical research company’s stock worth $6,146,000 after purchasing an additional 97,353 shares during the period. 91.88% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: Yield Curve

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.